WELLESLEY HILLS, Mass., May 10, 2011 /PRNewswire/ -- On Friday, June 10, 2011 at twelve o'clock noon, NMT Medical, Inc. intellectual property, which has been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP will be liquidated for the benefit of NMT Medical creditors.
NMT Medical, Inc. was an advanced medical technology company that designed, developed, manufactured and marketed proprietary implant technologies that allowed interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. More than 32,000 patients have been treated globally with its minimally invasive, catheter-based implant technology.
The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon. Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office – [email protected] or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn, Warnke & Gayton (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-seven (37) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX Pharmaceuticals, Inc. and Source MDx.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or [email protected]
SOURCE Joseph F. Finn, Jr., C.P.A.
Advertisement
NMT Medical, Inc. was an advanced medical technology company that designed, developed, manufactured and marketed proprietary implant technologies that allowed interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. More than 32,000 patients have been treated globally with its minimally invasive, catheter-based implant technology.
Advertisement
The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon. Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office – [email protected] or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn, Warnke & Gayton (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-seven (37) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX Pharmaceuticals, Inc. and Source MDx.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or [email protected]
SOURCE Joseph F. Finn, Jr., C.P.A.
